Michael Makris on Japan’s Breakthrough FVIII Variants for Hemophilia A
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn:
”Important paper from Japan published in Blood.
The authors have developed FVIII variants with increased specific activity, which can potentially be used for gene therapy in hemophilia A.
These would be the equivalent of the Padua variant for FIX and can be used at much lower doses.
Even when used at 1/30th of the dose of Roctavian in macaques, supraphysiological FVIII levels were achieved.
No human studies yet.”
Read the full article here.
Article: Engineered coagulation factor VIII with enhanced secretion and coagulation potential for hemophilia A gene therapy
Authors: Yuji Kashiwakura, Yuto Nakajima, Kio Horinaka, Tiago J. S. Lopes, Yuma Furuta, Yuki Yamaguchi, Nemekhbayar Baatartsogt, Morisada Hayakawa, Yuko Katakai, Susumu Uchiyama, Osamu Nureki, Keiji Nogami, Tsukasa Ohmori
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 23, 2026, 17:06Wolfgang Miesbach: HOPE-B Challenges 20 Years of Exclusion Criteria
-
Jan 23, 2026, 16:56Oliver Tiebel: Great and Unique Compilation of Current Knowledge on VWD
-
Jan 23, 2026, 16:46Soumya Mukherjee on Amyloid-β Isoform Modifications in CAA and Alzheimer’s
-
Jan 23, 2026, 16:32Amit Srivastava Edits The New Springer Protocols Volume on Extracellular Vesicles
-
Jan 23, 2026, 14:42David Stegner on PITTs Exacerbating Severe Inflammation
-
Jan 23, 2026, 14:30Christian Schulze: Time to Say Good-Bye to The “Obesity Paradox”?
-
Jan 23, 2026, 14:16Ahmed Nasreldein In The 1st Podcast Episode of International Journal of Stroke
-
Jan 23, 2026, 13:53Omar Shaltout: When Hematology Meets Gastroenterology in the ICU
-
Jan 23, 2026, 13:39Harshal Kale Invites You to WFH Webinar on World Health Assembly Resolution on Bleeding Disorders